13 Dec Atopic Dermatitis- Eczema: New Antibody Therapy Has Potential to Modify Disease Course
MedicalResearch.com Interview with:
Dr. Emma Guttman-Yassky, MD, PhD
Waldman Professor and System Chair
The Kimberly and Eric J. Waldman Department of Dermatology
Director, Center of Excellence in Eczema
Director, Laboratory of Inflammatory Skin Diseases
Icahn School of Medicine at Mount Sinai
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The background for this study are studies that show that OX40 is a pathway that is upregulated in patients with atopic dermatitis (or eczema). OX40 is involved in activation of immune molecules associated with allergy and atopy, and also with formation of memory immune cells that are required for disease recurrence. The hypothesis to the study was that giving an OX40 antagonist will not only ameliorate the disease but perhaps have a remittive effect in that the disease will not come back.
Indeed all drug doses were significantly effective at week 16, the primary endpoint compared to placebo and continued to improve towards week 36, the secondary endpoint. In addition, the responders to treatment maintained their responses for an additional 20 weeks, which is unusual, suggesting a potential for disease modification.
MedicalResearch.com: What should readers take away from your report?
Response: That new treatments with potential disease modification (meaning that treatment will be possibly given infrequently or even the idea that we can stop treatment as some point without the disease recurrence, may be possible in the not far future.
MedicalResearch.com: What recommendations do you have for future research as a results of this study?
Response: A phase 3 study is starting that will also involve adolescents. If it indeed works well and shows the same data, I would like to see this drug going into children where we need to see treatments that have a disease modifying effects so that children do not get treatment all their lives.
MedicalResearch.com: Is there anything else you would like to add? Any disclosures?
Response: It is an exciting possible new treatments that if it works it will open a new era of disease modification in adults and importantly in children.
Disclosures: I was the principal investigator for the study and am a consultant to Kyowa and Amgen that now co-develop the drug.
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
Guttman-Yassky, Emma et al.
The Lancet, Volume 0, Issue 0
Published:December 09, 2022DOI
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.